To study the efficacy of Mustadi Churna in Pandu Roga w.s.r. Haemoglobin percentage

Pandu is the disease which is described by all major classical texts of Ayurveda. As per Ayurvedic text in Pandu Roga the color of body look like polen grain of Ketki flower. Due to its similarity we can correlate Pandu Roga with modern science anaemia disease. Rasavaha and Raktavaha Strotasa are commonly involved in pathogenesis of Pandu Roga. Pandu if not treated properly can bring serious consequences to our health. Different Kalpas were described in Ayurved Samhitas for the treatment of Pandu Roga. In present study we use Mustadi Churna in the treatment of Pandu Roga and assess its efficacy

In vitro absorption studies of acyclovir using natural permeation enhancers

Gastroretentive Delivery Systems are employed to improve the bioavailability of drugs which are absorbed through upper part of GIT, by increasing their retention time. Incorporation of permeability enhancers in the formulations of such drugs can further increase their bioavailability; however their use in the formulations is questionable due to the toxicity exhibited by them. Acyclovir is a class III drug having low oral bioavailability due to improper absorption. Mucoadhesive tablets of acyclovir containing natural permeation enhancers were prepared by direct compression and evaluated for mucoadhesion strength, in-vitro dissolution parameters and in-vitro absorption studies. The formulations containing Aloe vera extract showed increase in the mucoadhesion strength and retarded the drug release. The in-vitro absorption studies revealed that the formulations containing Aloe vera extract (Enhancement Ratio 1.94) and chausath prahar pippal (Enhancement Ratio 1.87) showed significant increase in the permeation of the drug. The studies led to the conclusion that by formulating mucoadhesive tablets of acyclovir containing natural permeation enhancers increased the permeability, thus proving to be the cheaper and easily available alternative to the other permeation enhancers.Colegio de Farmacéuticos de la Provincia de Buenos Aire

Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer

IMPORTANCE: Black men have higher incidence and mortality from prostate cancer. Whether precision oncology disparities affect Black men with metastatic castration-resistant prostate cancer (mCRPC) is unknown. OBJECTIVE: To compare precision medicine data and outcomes between Black and White men with mCRPC. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data collected by the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) consortium, a multi-institutional registry with linked clinicogenomic data, from April 2020 to December 2021. Participants included Black and White patients with mCRPC with molecular data. Data were analyzed from December 2021 to May 2023. EXPOSURES: Database-reported race and ethnicity. MAIN OUTCOMES AND MEASURES: The primary outcome was the frequency of actionable molecular data, defined as the presence of mismatch repair deficiency (MMRD) or high microsatellite instability (MSI-H), homologous recombination repair deficiency, or tumor mutational burden of 10 mutations per megabase or greater. Secondary outcomes included the frequency of other alterations, the type and timing of genomic testing performed, and use of targeted therapy. Efficacy outcomes were prostate-specific antigen response rate, site-reported radiographic response, and overall survival. RESULTS: A total of 962 eligible patients with mCRPC were identified, including 204 Black patients (21.2%; median [IQR] age at diagnosis, 61 [55-67] years; 131 patients [64.2%] with Gleason scores 8-10; 92 patients [45.1%] with de novo metastatic disease) and 758 White patients (78.8%; median [IQR] age, 63 [57-69] years; 445 patients [58.7%] with Gleason scores 8-10; 310 patients [40.9%] with de novo metastatic disease). Median (IQR) follow-up from mCRPC was 26.6 (14.2-44.7) months. Blood-based molecular testing was more common in Black men (111 men [48.7%]) than White men (317 men [36.4%]; P \u3c .001). Rates of actionable alterations were similar between groups (65 Black men [32.8%]; 215 White men [29.1%]; P = .35), but MMRD or MSI-H was more common in Black men (18 men [9.1]) than White men (36 men [4.9%]; P = .04). PTEN alterations were less frequent in Black men than White men (31 men [15.7%] vs 194 men [26.3%]; P = .003), as were TMPRSS alterations (14 men [7.1%] vs 155 men [21.0%]; P \u3c .001). No other differences were seen in the 15 most frequently altered genes, including TP53, AR, CDK12, RB1, and PIK3CA. Matched targeted therapy was given less frequently in Black men than White men (22 men [33.5%] vs 115 men [53.5%]; P = .008). There were no differences in response to targeted therapy or survival between the two cohorts. CONCLUSIONS AND RELEVANCE: This cohort study of men with mCRPC found higher frequency of MMRD or MSI-H and lower frequency of PTEN and TMPRSS alterations in Black men compared with White men. Although Black men received targeted therapy less frequently than White men, no differences were observed in clinical outcomes

Synthesis of tertiary arsines containing N,N'-dimethylaminobenzyl group

983-985Tertiary arsines of the type [RAs(C6H4CH2NMe2)2] (R = Me, Et, Ph) and [Me2As(C6H4CH2NMe2)] have been prepared by the salt elimination reactions of Li[C6H4CH2NMe2)] with an appropriate organoarsenic (III) halide. These arsines have been characterized by elemental analysis, IR, mass and NMR (1H and 13C) spectral data

Triphenylantimony(V)dichloride molecular adducts with some thiosemicarbazones

1667-1671The reaction of triphenylantimony(V)dichloride with one mole equivalent of thiosemicarbazone ligands yields the molecular adducts of the type Ph3SbCl2. NᴖS (NᴖS = thiosemicarbazones). These compounds have been characterized by elemental analysis, IR and 1H and 13C NMR spectral data and conductometric measurements. The structures of these molecular adducts have been proposed on the basis of spectroscopic data